Caplin Point Laboratories Limited
Our verdict
Quality (91/100) does the heavy lifting; momentum (13/100) is the drag.
Our fair value
Undervalued by 33%Buy-below (20% margin of safety): ₹2,216.79
Our blended model reads Caplin Point Laboratories Limited as a Buy at 68/100. On 29.9x trailing earnings it sits cheaper than the Healthcare median of about 37.4x. The price is about 27% below its 52-week high of ₹2,867.4 and 39% above the low of ₹1,499.51. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹2,505 implies about 20% upside across 2 analysts. It clears 10 of 13 investability checks, with durability 91, valuation 61 and momentum 13 on our 0–100 scales.
Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹2,216.79.
Analyst views
1-year price
EOD · 2026-11-2052-week range
-27.30% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy68Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 19.9%
- Pass: Low debt (D/E < 0.5): 0.00x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 19%
- Pass: Earnings growing: 19%
- Pass: Net margin ≥ 10%: 29.3%
- Pass: Current ratio > 1.5: 6.70
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 29.58
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter73.6%
- Institutions5.6%
- Public & other20.8%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (19.9%).
- Lightly leveraged balance sheet.
- Healthy profit margin (29.3%).
- Financially solid — Altman Z 29.58.
Opportunities
- Earnings growing (19% YoY).
- Revenue growing (19% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~33% below our estimated fair value.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
- Weak Piotroski score (3/9).
About Caplin Point Laboratories Limited
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled
Caplin Point Laboratories Limited — frequently asked questions
Is Caplin Point Laboratories Limited a buy, hold or sell?
TickerMagic currently rates Caplin Point Laboratories Limited (CAPLIPOINT) a Buy, based on a blended score of 68/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Caplin Point Laboratories Limited's fair value?
Our blended DCF and relative-valuation model estimates Caplin Point Laboratories Limited's fair value at about ₹2,770.99, versus a current price of ₹2,084.6 — roughly 33% upside. On that basis the stock looks undervalued by 33%.
Is Caplin Point Laboratories Limited financially healthy?
Caplin Point Laboratories Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Caplin Point Laboratories Limited's share price performed?
Caplin Point Laboratories Limited is down 17% over three months, and last traded at ₹2,084.6. Past performance doesn't predict future returns.
More in Healthcare
Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.